Browse TACSTD2

Summary
SymbolTACSTD2
Nametumor-associated calcium signal transducer 2
Aliases TROP2; GA733-1; EGP-1; M1S1; EGP1; GA7331; GP50; 40kD glycoprotein, identified by monoclonal antibody GA733; ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF00086 Thyroglobulin type-1 repeat
Function

May function as a growth factor receptor.

> Gene Ontology
 
Biological Process GO:0001655 urogenital system development
GO:0001657 ureteric bud development
GO:0001658 branching involved in ureteric bud morphogenesis
GO:0001667 ameboidal-type cell migration
GO:0001763 morphogenesis of a branching structure
GO:0001822 kidney development
GO:0001823 mesonephros development
GO:0007015 actin filament organization
GO:0007162 negative regulation of cell adhesion
GO:0007601 visual perception
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010633 negative regulation of epithelial cell migration
GO:0010639 negative regulation of organelle organization
GO:0010721 negative regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010771 negative regulation of cell morphogenesis involved in differentiation
GO:0010810 regulation of cell-substrate adhesion
GO:0010812 negative regulation of cell-substrate adhesion
GO:0022604 regulation of cell morphogenesis
GO:0030031 cell projection assembly
GO:0030038 contractile actin filament bundle assembly
GO:0030336 negative regulation of cell migration
GO:0031032 actomyosin structure organization
GO:0031345 negative regulation of cell projection organization
GO:0031529 ruffle organization
GO:0031589 cell-substrate adhesion
GO:0032231 regulation of actin filament bundle assembly
GO:0032232 negative regulation of actin filament bundle assembly
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0034446 substrate adhesion-dependent cell spreading
GO:0035239 tube morphogenesis
GO:0040013 negative regulation of locomotion
GO:0043149 stress fiber assembly
GO:0048754 branching morphogenesis of an epithelial tube
GO:0048863 stem cell differentiation
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050953 sensory perception of light stimulus
GO:0051017 actin filament bundle assembly
GO:0051271 negative regulation of cellular component movement
GO:0051492 regulation of stress fiber assembly
GO:0051493 regulation of cytoskeleton organization
GO:0051494 negative regulation of cytoskeleton organization
GO:0051497 negative regulation of stress fiber assembly
GO:0060491 regulation of cell projection assembly
GO:0060562 epithelial tube morphogenesis
GO:0060675 ureteric bud morphogenesis
GO:0060688 regulation of morphogenesis of a branching structure
GO:0060993 kidney morphogenesis
GO:0061138 morphogenesis of a branching epithelium
GO:0061217 regulation of mesonephros development
GO:0061218 negative regulation of mesonephros development
GO:0061326 renal tubule development
GO:0061333 renal tubule morphogenesis
GO:0061572 actin filament bundle organization
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072009 nephron epithelium development
GO:0072028 nephron morphogenesis
GO:0072073 kidney epithelium development
GO:0072078 nephron tubule morphogenesis
GO:0072080 nephron tubule development
GO:0072088 nephron epithelium morphogenesis
GO:0072163 mesonephric epithelium development
GO:0072164 mesonephric tubule development
GO:0072171 mesonephric tubule morphogenesis
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090183 regulation of kidney development
GO:0090185 negative regulation of kidney development
GO:0090189 regulation of branching involved in ureteric bud morphogenesis
GO:0090191 negative regulation of branching involved in ureteric bud morphogenesis
GO:0097178 ruffle assembly
GO:1900024 regulation of substrate adhesion-dependent cell spreading
GO:1900025 negative regulation of substrate adhesion-dependent cell spreading
GO:1900027 regulation of ruffle assembly
GO:1900028 negative regulation of ruffle assembly
GO:1905330 regulation of morphogenesis of an epithelium
GO:1905331 negative regulation of morphogenesis of an epithelium
GO:2000027 regulation of organ morphogenesis
GO:2000146 negative regulation of cell motility
GO:2000736 regulation of stem cell differentiation
GO:2000738 positive regulation of stem cell differentiation
Molecular Function -
Cellular Component GO:0009925 basal plasma membrane
GO:0016323 basolateral plasma membrane
GO:0016328 lateral plasma membrane
GO:0045178 basal part of cell
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolTACSTD2
Nametumor-associated calcium signal transducer 2
Aliases TROP2; GA733-1; EGP-1; M1S1; EGP1; GA7331; GP50; 40kD glycoprotein, identified by monoclonal antibody GA733; ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TACSTD2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TACSTD2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23674207Prostate CarcinomaInhibit immunityTF12 is a trivalent bispecific antibody that consists of two anti-TROP-2 Fab fragments and one anti-histamine-succinyl-glycine (HSG) Fab fragment. TROP-2-expressing PC can be pretargeted efficiently with TF12, with very rapid uptake of the radiolabeled hapten-peptide, IMP288, sensitive immuno-PET, and effective therapy.
21453957Ovarian CancinomaInhibit immunity (T/NK cell function); immunotherapy targetHigh-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. All primary ovarian cancer cell lines expressing Trop-2 were highly sensitive to hRS7-mediated ADCC in vitro (range of killing: 19.3% to 40.8%) (p<0.001).
Summary
SymbolTACSTD2
Nametumor-associated calcium signal transducer 2
Aliases TROP2; GA733-1; EGP-1; M1S1; EGP1; GA7331; GP50; 40kD glycoprotein, identified by monoclonal antibody GA733; ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TACSTD2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTACSTD2
Nametumor-associated calcium signal transducer 2
Aliases TROP2; GA733-1; EGP-1; M1S1; EGP1; GA7331; GP50; 40kD glycoprotein, identified by monoclonal antibody GA733; ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TACSTD2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1260.875
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.1090.411
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.0490.319
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.7480.242
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6680.815
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8440.807
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0260.979
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0990.943
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1950.893
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1760.873
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9940.48
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0560.761
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TACSTD2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTACSTD2
Nametumor-associated calcium signal transducer 2
Aliases TROP2; GA733-1; EGP-1; M1S1; EGP1; GA7331; GP50; 40kD glycoprotein, identified by monoclonal antibody GA733; ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TACSTD2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTACSTD2
Nametumor-associated calcium signal transducer 2
Aliases TROP2; GA733-1; EGP-1; M1S1; EGP1; GA7331; GP50; 40kD glycoprotein, identified by monoclonal antibody GA733; ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TACSTD2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TACSTD2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTACSTD2
Nametumor-associated calcium signal transducer 2
Aliases TROP2; GA733-1; EGP-1; M1S1; EGP1; GA7331; GP50; 40kD glycoprotein, identified by monoclonal antibody GA733; ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TACSTD2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTACSTD2
Nametumor-associated calcium signal transducer 2
Aliases TROP2; GA733-1; EGP-1; M1S1; EGP1; GA7331; GP50; 40kD glycoprotein, identified by monoclonal antibody GA733; ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TACSTD2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTACSTD2
Nametumor-associated calcium signal transducer 2
Aliases TROP2; GA733-1; EGP-1; M1S1; EGP1; GA7331; GP50; 40kD glycoprotein, identified by monoclonal antibody GA733; ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TACSTD2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTACSTD2
Nametumor-associated calcium signal transducer 2
Aliases TROP2; GA733-1; EGP-1; M1S1; EGP1; GA7331; GP50; 40kD glycoprotein, identified by monoclonal antibody GA733; ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TACSTD2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.